Page 1

August 12 , 2021 MindMed MindMed Announces 2021 Q2 Financial Results ; Cash Balance of $ 157 USD Million ( $ 195 CAD Million ) to Execute on Diverse Clinical Pipeline NEW YORK , Aug. 12 , 2021 / CNW / -- MindMed ( Nasdaq : MNMD ) , ( NEO : MMED ) , ( DE : MMQ ) , a leading biotech company developing psychedelic - inspired therapies , has announced its quarterly financial results for the quarter ended June 30 , 2021 . MindMed Q2 2021 Financial Highlights ( in USD ) • Total assets as of June 30 , 2021 were $ 194 million , including $ 157 million in cash • Net Cash Used in Operating Activities of $ 12 million for the quarter ended June 30 , 2021 • Net and comprehensive loss of $ 36 million for the quarter ended June 30 , 2021 Q2 2021 Business Highlights • MindMed launched Project Angie , targeting the treatment of pain with psychedelics • MindMed launched a collaboration with Nextage Therapeutics to explore applications of psychedelics in a brain targeting liposome delivery system • MindMed and the Liechti Lab published the first pharmacogenetic data on LSD • MindMed appointed Dr. Sarah Vinson to its Board of Directors • MindMed appointed Drs . Maurizio Fava and Peter Bergethon to its Scientific Advisory Board • MindMed completed a transition of its Chief Executive Officer Management Update & Earnings Call Management will host an earnings call to review Q2 financials and business developments on Monday , August 16th , 2021 at 4:00 pm EDT . Details are below : https://mindmed-co.zoom.us/webinar/register/WN_Jk5SnZAXQUGgAxVU5-QceQ